Company intelligence / Profile preview
Mesentech
Vancouver, British Columbia, Canadamesentech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mesentech has developed a proprietary tissue-selective drug delivery platform that enables targeted pharmaceutical distribution to specific tissues, minimizing off-target toxicity. Its lead candidate MES1022, a bone-selective EP4 agonist, entered Phase I clinical trials in September 2024 for accelerating bone fracture healing. The company also has preclinical programs targeting bone cancer and improving osseointegration for orthopedic implants. Early clinical results are not yet published but the first patients have been dosed with MES1022 as of late September 2024.
- Therapeutic areas
- OtherOncologyRheumatology
- Modalities
- Small molecules (prostaglandin analogs, EP4 agonists)Prodrug technology (tissue-targeted delivery)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Mesentech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesentech.